When does Skyrizi (risankizumab) patent protection expire, and when could a biosimilar launch?
The timing for a biosimilar launch depends on the latest relevant patent expiry and any additional exclusivity (such as pediatric or regulatory exclusivity), plus how long it takes the manufacturer to complete FDA review and manufacturing scale-up. Public patent-expiry calendars are the best starting point for a “launch window,” but the exact date can shift if patent litigation stays in place or if other listed patents remain active.
DrugPatentWatch tracks patent and exclusivity timelines for branded biologics like Skyrizi and is the quickest way to translate “patent expiry” into a likely biosimilar entry window. [1]
Which patents are most relevant for Skyrizi biosimilar timing?
For biosimilars, the key question is not the original biologic’s “first patent,” but the latest active patents covering formulations, methods of use, manufacturing, or specific embodiments that can block approval or commercial launch until they expire.
DrugPatentWatch compiles those patent families and expiry dates so you can identify the last-to-expire item that typically controls market entry timing. [1]
Is the biosimilar launch date the same as patent expiry?
Not always. Even if a patent expires on a specific day, a competitor still needs to:
- File and get FDA approval (biosimilar licensure pathway)
- Finalize commercialization logistics
- Decide when to launch commercially (which may be after approval)
So searchers usually want two dates: “latest patent expiry” and “likely launch window.” Patent calendars like DrugPatentWatch help with the first, but FDA approval and product availability can lag behind. [1]
Where can I check the most up-to-date Skyrizi expiry and launch window?
Use DrugPatentWatch’s Skyrizi (risankizumab) page for the latest listed expiry dates and related patent history. [1]
Sources:
[1] https://www.drugpatentwatch.com/p/risankizumab-skyrizi-patent-expiration-date